| Edmund John Forte, MD | |
|
101 Milford St, Salisbury, MD 21804-6952 | |
| (410) 749-9290 | |
| (410) 543-9087 |
| Full Name | Edmund John Forte |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 101 Milford St, Salisbury, Maryland |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609938224 | NPI | - | NPPES |
| T6990003 | Other | MD | CAREFIRST BLUE CHOICE |
| 276801100 | Medicaid | MD | |
| 4410369 | Other | AETNA | |
| 0000102201 | Medicaid | DE | |
| 006356231 | Medicaid | VA | |
| 20885 | Other | MAMSI | |
| 352275 | Other | MD | CAREFIRST BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | D0036073 (Maryland) | Primary |
| Entity Name | Peninsula Eye Center Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164546974 PECOS PAC ID: 0244314235 Enrollment ID: O20080229000221 |
News Archive
Scientists have discovered that breaking a biological signaling system in an embryo allows them to change the destiny of a cell.
The Alcon Independent Director Committee (the "IDC") today announced that RiskMetrics Group, Inc. and Glass Lewis & Co., two global leaders in risk management, corporate governance and proxy advisory services, have both recommended that Alcon minority shareholders vote against all five of Novartis AG's ("Novartis") designees to the Alcon board of directors. As previously announced, pursuant to the terms of agreements between Novartis and Nestlé SA entered into in 2008, Alcon shareholders will vote on the conditional election of Novartis' board designees at an extraordinary general meeting on August 16, 2010.
Children with cancer have a good chance of surviving the disease-today more than 80 percent survive because of advances in treatment and care. However, recent studies have shown that some of these more than 420,000 U.S. childhood cancer survivors face future health-related challenges as they become adults such as a second cancer diagnosis, cardiac failure, or other severe medical complications.
Medical science liaisons are increasingly forming relationships with key opinion leaders who serve on reimbursement committees, according to a study by Cutting Edge Information.
Now, a new study by researchers at Yale University and published on the preprint server medRxiv in August 2020 reports that the use of two drug categories, namely, JAK inhibitors and Type I interferons (IFNs), is associated with a dramatic improvement in mortality in COVID-19.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edmund John Forte, MD 101 Milford St, Salisbury, MD 21804-6952 Ph: (410) 749-9290 | Edmund John Forte, MD 101 Milford St, Salisbury, MD 21804-6952 Ph: (410) 749-9290 |
News Archive
Scientists have discovered that breaking a biological signaling system in an embryo allows them to change the destiny of a cell.
The Alcon Independent Director Committee (the "IDC") today announced that RiskMetrics Group, Inc. and Glass Lewis & Co., two global leaders in risk management, corporate governance and proxy advisory services, have both recommended that Alcon minority shareholders vote against all five of Novartis AG's ("Novartis") designees to the Alcon board of directors. As previously announced, pursuant to the terms of agreements between Novartis and Nestlé SA entered into in 2008, Alcon shareholders will vote on the conditional election of Novartis' board designees at an extraordinary general meeting on August 16, 2010.
Children with cancer have a good chance of surviving the disease-today more than 80 percent survive because of advances in treatment and care. However, recent studies have shown that some of these more than 420,000 U.S. childhood cancer survivors face future health-related challenges as they become adults such as a second cancer diagnosis, cardiac failure, or other severe medical complications.
Medical science liaisons are increasingly forming relationships with key opinion leaders who serve on reimbursement committees, according to a study by Cutting Edge Information.
Now, a new study by researchers at Yale University and published on the preprint server medRxiv in August 2020 reports that the use of two drug categories, namely, JAK inhibitors and Type I interferons (IFNs), is associated with a dramatic improvement in mortality in COVID-19.
› Verified 8 days ago
William Jay Doyle, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 101 Milford St, Salisbury, MD 21804 Phone: 410-749-9290 Fax: 410-543-9087 | |
Zaaira Mushtaq Ahmad, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6511 Deer Pointe Dr, Salisbury, MD 21804 Phone: 410-546-8037 Fax: 410-546-8038 | |
John W. Butler, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6511 Deer Pointe Drive, Salisbury, MD 21804 Phone: 410-546-8037 Fax: 410-546-8038 | |
Gary P Luppens, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 101 Milford St, Salisbury, MD 21804 Phone: 410-749-9290 Fax: 410-543-9087 | |
Dr. Jeffrey D Benner, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6511 Deer Pointe Drive, Salisbury, MD 21804 Phone: 410-546-8037 Fax: 410-546-8038 | |
Paul Joseph Lagonigro, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 31455 Winterplace Pkwy, Salisbury, MD 21804 Phone: 410-742-4100 Fax: 410-742-4156 | |
Dr. James F Gallagher, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 31519 Winterplace Pkwy, Suite 1, Salisbury, MD 21804 Phone: 410-546-2500 Fax: 410-546-5005 |